About one month ago, Central Oregon was struck by stormy weather that affected close to 500 acres of industrial hemp. Four weeks later, farmers are saying that they may not suffer a complete loss since the plants are bouncing back. Matt Cyrus, the president of Deschutes County Farm Bureau, says some of the plants that … Continue reading “Oregon Storm Damage Update: Hemp Recovers, But Flower Development Still Uncertain”
The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year 95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated Lexaria’s DIAB-A22-1 pre-clinical diabetes study … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems”
Lexaria is a drug delivery technology company developing DehydraTECH-CBD as a prospective registered treatment for hypertension and potentially other disease states beyond hypertension The company has undertaken multiple de-risking hypertension studies that have not only evidenced that DehydraTECH-CBD is safe and well tolerated, but have also shown that it reduces blood pressure and arterial stiffness … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD”
Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline”
Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments”
Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster … Continue reading “HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs”
Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure”
Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer””
Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products Lexaria has undertaken various studies … Continue reading “As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation”
The study is available for public viewing and is entitled “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants” (https://cnw.fm/Aq36i) Dr. Richard van Breeman, who headed the independent study, explained that smoking and vaping cannabinoids are ineffective against preventing SARS-CoV-2, whereas oral delivery methods are effective Lexaria has been studying and researching the oral … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study”
